MerryLife Biomedical, a clinical-stage biotechnology company focused on neurodegenerative disorders, has announced positive Phase I results for TML-6, its investigational oral therapy for Alzheimer’s Disease (AD). The study showed that TML-6 was generally well tolerated and demonstrated a favourable safety profile, supporting further clinical development.

TML-6 is designed to regulate the autolysosomal system and interconnected cellular pathways involved in protein clearance, neuroinflammation, oxidative stress and age-related neuronal dysfunction, biological mechanisms widely recognised as central to the progression of Alzheimer’s and Parkinson’s diseases. By targeting multiple disease-driving pathways, the therapy aims to address the complex nature of neurodegeneration beyond single-target approaches.

Dr. Ih-Jen Su, Chief Executive Officer, MerryLife Biomedical, stated that neurodegenerative diseases arise from complex and interconnected biological processes that are difficult to treat with single-target therapies. 

He added that TML-6’s multi-targeted mechanism, oral formulation and favourable safety profile position it as a promising candidate for earlier intervention aimed at slowing disease progression in areas of high unmet medical need.

Following the positive Phase I findings, the company plans to initiate a global Phase II clinical programme in early Alzheimer’s disease. The study will enrol approximately 210 participants with mild cognitive impairment and mild dementia across sites in the United States, Sweden and Taiwan. The Phase II trial will further assess safety and tolerability while also evaluating disease-related biomarkers linked to multi-pathway modulation.

In addition to Alzheimer’s disease, the company is exploring the potential of TML-6 in Parkinson’s disease, where overlapping pathological mechanisms contribute to disease progression. MerryLife intends to present additional preclinical findings and clinical development updates at the AD/PD™ 2026 International Conference in Copenhagen on March 19, 2026.